Cover Image
市場調查報告書

Lytix Biopharma AS的產品平台分析

Lytix Biopharma AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 200973
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Lytix Biopharma AS的產品平台分析 Lytix Biopharma AS - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 33 Pages
簡介

本報告提供Lytix Biopharma AS的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,以及暫停中的計劃等資訊。

Lytix Biopharma AS的基本資料

Lytix Biopharma AS概要

  • 主要資訊
  • 企業資料

Lytix Biopharma AS:R&D概要

  • 主要的治療範圍

Lytix Biopharma AS:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Lytix Biopharma AS:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Lytix Biopharma AS:藥物簡介

  • LTX-109
  • LTX-315
  • 癌症治療藥
  • CTLA4抑制劑
  • 激酶為目標的藥物
  • 針對腫瘤用小分子

Lytix Biopharma AS:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lytix Biopharma AS:最近的開發平台趨勢

Lytix Biopharma AS:暫停中的計劃

Lytix Biopharma AS:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07321CDB

Summary

Global Markets Direct's, 'Lytix Biopharma AS - Product Pipeline Review - 2015', provides an overview of the Lytix Biopharma AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lytix Biopharma AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lytix Biopharma AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lytix Biopharma AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lytix Biopharma AS's pipeline products

Reasons to buy

  • Evaluate Lytix Biopharma AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lytix Biopharma AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lytix Biopharma AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lytix Biopharma AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lytix Biopharma AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lytix Biopharma AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lytix Biopharma AS Snapshot
    • Lytix Biopharma AS Overview
    • Key Information
    • Key Facts
  • Lytix Biopharma AS - Research and Development Overview
    • Key Therapeutic Areas
  • Lytix Biopharma AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Lytix Biopharma AS - Pipeline Products Glance
    • Lytix Biopharma AS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Lytix Biopharma AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lytix Biopharma AS - Drug Profiles
    • LTX-109
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LTX-315
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit CTLA4 for Oncology + LTX-315
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Target Kinase for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lytix Biopharma AS - Pipeline Analysis
    • Lytix Biopharma AS - Pipeline Products by Target
    • Lytix Biopharma AS - Pipeline Products by Route of Administration
    • Lytix Biopharma AS - Pipeline Products by Molecule Type
    • Lytix Biopharma AS - Pipeline Products by Mechanism of Action
  • Lytix Biopharma AS - Recent Pipeline Updates
  • Lytix Biopharma AS - Dormant Projects
  • Lytix Biopharma AS - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lytix Biopharma AS, Key Information
  • Lytix Biopharma AS, Key Facts
  • Lytix Biopharma AS - Pipeline by Indication, 2015
  • Lytix Biopharma AS - Pipeline by Stage of Development, 2015
  • Lytix Biopharma AS - Monotherapy Products in Pipeline, 2015
  • Lytix Biopharma AS - Combination Treatment Modalities in Pipeline, 2015
  • Lytix Biopharma AS - Phase II, 2015
  • Lytix Biopharma AS - Phase I, 2015
  • Lytix Biopharma AS - Preclinical, 2015
  • Lytix Biopharma AS - Discovery, 2015
  • Lytix Biopharma AS - Pipeline by Target, 2015
  • Lytix Biopharma AS - Pipeline by Route of Administration, 2015
  • Lytix Biopharma AS - Pipeline by Molecule Type, 2015
  • Lytix Biopharma AS - Pipeline Products by Mechanism of Action, 2015
  • Lytix Biopharma AS - Recent Pipeline Updates, 2015
  • Lytix Biopharma AS - Dormant Developmental Projects,2015
  • Lytix Biopharma AS, Other Locations

List of Figures

  • Lytix Biopharma AS - Pipeline by Top 10 Indication, 2015
  • Lytix Biopharma AS - Pipeline by Stage of Development, 2015
  • Lytix Biopharma AS - Monotherapy Products in Pipeline, 2015
  • Lytix Biopharma AS - Pipeline by Top 10 Target, 2015
  • Lytix Biopharma AS - Pipeline by Top 10 Route of Administration, 2015
  • Lytix Biopharma AS - Pipeline by Top 10 Molecule Type, 2015
  • Lytix Biopharma AS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top